 | |
| Company type | Public |
|---|---|
| Nasdaq: INO | |
| Industry | Biotechnology |
| Founded | 1999 |
| Headquarters | Plymouth Meeting, Pennsylvania |
Key people | Jacqueline Shea, Ph.D. (president and CEO) |
| Products | DNA-based Medicines and Vaccines[1] |
| Revenue |  $7 Million(2020)[2] |
Number of employees | 262 [3] |
| Website | inovio.com |
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).[4][5]
- ^ "Home". inovio.com.
- ^ "Inovio Pharmaceuticals Revenue 2006-2021 | INO".
- ^ "Inovio Pharmaceuticals Number of Employees 2006-2021 | INO".
- ^ Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie; Mayhew, Stephen (9 April 2020). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.
- ^ "COVID-19 vaccine tracker (Select vaccine tab)". Airtable. 22 June 2020. Retrieved 23 June 2020.